Boron Containing (e.g., Boron Containing Complexes, Salts, Etc.) Patents (Class 564/8)
  • Patent number: 10344043
    Abstract: The present document describes compounds resulting from the complexation of quaternary ammonium compounds with boric acid and/or its derivatives, and methods of making the same, and methods of using the same for the treatment of pathogenic infections.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: July 9, 2019
    Inventors: Tien Canh Le, Giuliano Lafrenière Di Fruscia
  • Patent number: 9604850
    Abstract: A method of purifying ammonia borane is provided in which crude ammonia borane is dissolved in an organic solvent, such as an ether, and mixed with a basic aqueous solution to form a two-phase system. The pH of the aqueous solution and the temperature are adjusted to increase the solubility of the impurities and decrease the solubility of the ammonia borane in the basic aqueous solution, without causing decomposition of the ammonia borane. The impurities are separated from the crude ammonia borane solution, the mixture is phase-separated and the dissolved ammonia borane is isolated from the organic solvent fraction. High purity ammonia borane is obtained.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: March 28, 2017
    Assignee: WeylChem Sustainable Materials, LLC
    Inventor: Kevin Joel Drost
  • Patent number: 9133036
    Abstract: The present invention relates to a method for obtaining borazane, said method being suitable for obtaining borazane containing a low level of impurities. The borazane (obtained by reaction of at least one ammonium salt with at least one alkali and/or alkaline earth metal borohydride) in solution in THF is selectively precipitated with a non-solvent. The precipitated borazane can further be purified by selective dissolution. The borazane obtained after selective precipitation and dissolution contains less than 1% by weight of impurities and/or does not exhibit exothermic decomposition in the solid state with a temperature range of the endothermic melting peak above 110° C.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: September 15, 2015
    Assignee: HERAKLES
    Inventors: Jean-Philippe Goudon, Joël Renouard
  • Publication number: 20150094469
    Abstract: A borate moiety-contained linker and a bio-sensing element containing the same are disclosed. The borate moiety-contained linker can be used to modify a sensing molecule and connect the sensing molecule to a substrate to form the bio-sensing element.
    Type: Application
    Filed: December 4, 2014
    Publication date: April 2, 2015
    Inventors: Yaw-Kuen LI, Mo-Yuan SHEN, Yu-Ju PIEN
  • Publication number: 20150080339
    Abstract: The present disclosure relates to boron-based 4-hydroxytamoxifen and endoxifen prodrugs and the synthesis of the same. Further, the present disclosure teaches the utilization of the boron-based 4-hydroxytamoxifen and endoxifen prodrugs in a treatment for breast cancer.
    Type: Application
    Filed: March 5, 2013
    Publication date: March 19, 2015
    Inventors: Guangdi Wang, Shilong Zheng, Quan Jiang, Qiu Zhong, Qiang Zhang
  • Patent number: 8981147
    Abstract: The present invention provides a novel ligand represented by the following formula and a novel transition metal complex having the ligand, which shows superior enantioselectivity and catalytic efficiency, particularly high catalyst activity, in various asymmetric synthesis reactions. A transition metal complex having, as a ligand, a compound represented by the formula wherein R4 is a hydrogen atom or a C1-6 alkyl group optionally having substituent(s), and R5 and R6 are each a C1-6 alkyl group optionally having substituent(s), or the formula is a group represented by the formula wherein ring B is a 3- to 8-membered ring optionally having substituent(s).
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: March 17, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Mitsuhisa Yamano, Mitsutaka Goto, Shinji Kawaguchi, Masatoshi Yamada, Jun-ichi Kawakami
  • Publication number: 20150072956
    Abstract: The present invention relates to novel cluster boron compounds and their use as sodium channel blockers. In particular, the novel cluster boron compounds may be lidocaine analogs where the aromatic ring of the lidocaine molecule is replaced with a cluster boron group. The invention also provides methods for making the cluster boron compounds comprising contacting a halogenated cluster boron with an amino acetamide in the presence of a catalyst, a proton acceptor, and a ligand.
    Type: Application
    Filed: September 13, 2012
    Publication date: March 12, 2015
    Applicant: The Curators of the University of Missouri
    Inventors: George R. Kracke, Yulia Sevryugina, Marion Frederick Hawthorne
  • Publication number: 20150057248
    Abstract: Embodiments of the invention are directed to compounds that are positive allosteric modulators of AMPA receptors.
    Type: Application
    Filed: September 1, 2014
    Publication date: February 26, 2015
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Jia Zhou, Haijun Chen, Kenneth M. Johnson, Cheng Z. Wang
  • Publication number: 20150031896
    Abstract: The present invention relates to the improvement of organic electroluminescent devices, in particular blue-emitting devices, by using compounds of the formula (1) as dopants in the emitting layer.
    Type: Application
    Filed: October 2, 2014
    Publication date: January 29, 2015
    Inventors: Horst Vestweber, Holger Heil, Philipp Stoessel, Arne Buesing, Amir Hossain Parham, Rocco Fortte
  • Patent number: 8921597
    Abstract: Methods for making polyaminoboric acid compounds are provided. The polyaminoboric acid compounds are made by reacting a polyamine with boric acid in the presence of a solvent to produce polyaminoboric acid compounds with more than one boron-nitrogen bond. The polyaminoboric acid compounds are useful as crosslinking agents for fracturing fluids.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: December 30, 2014
    Assignee: Baker Hughes Incorporated
    Inventors: Hong Sun, Qi Qu
  • Publication number: 20140373984
    Abstract: Disclosed are hypergolic salts with borane cluster anions that ignite spontaneously upon contact with nitric acid (from 70% to 100% in water) with short ignition delay. The salts, when added as trigger additive to combustible solvent or ionic liquids, make the resulting formulation hypergolic. The salts with borane cluster anions also shorten ignition delay in hypergols, such as RP-1, and additionally allow nitric acid to be used to replace liquid oxygen as an oxidizer. In some examples, the borane salts are formed in situ in an ionic liquid.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 25, 2014
    Inventors: Parker D. McCrary, Robin D. Rogers
  • Patent number: 8895534
    Abstract: Novel monosubstituted and disubstutituted oxaboroles and pharmaceutical compositions containing such oxaboroles are provided, which are useful for treating bacterial infections, as well as combinations of these oxaboroles with at least one additional therapeutically effective agent.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: November 25, 2014
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Stephen J. Baker, Vincent S. Hernandez, Rashmi Sharma, James A. Nieman, Tsutomu Akama, Yong-Kang Zhang, Jacob J. Plattner, Michael Richard Kevin Alley, Rajeshwar Singh, Fernando Rock
  • Patent number: 8871745
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: October 28, 2014
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Edward J. Olhava, Mihaela Diana Danca
  • Publication number: 20140315860
    Abstract: This invention relates to, among other items, benzoxaborole compounds and their use for treating bacterial infections.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 23, 2014
    Applicant: Anacor Pharmaceuticals, Inc.
    Inventors: Vincent S. HERNANDEZ, Charles Ding, Jacob J. Plattner, Michael Richard Kevin Alley, Fernando Rock, Suoming Zhang, Eric Easom, Xianfeng Li, Ding Zhou
  • Patent number: 8829156
    Abstract: The complex of the present invention containing an onium salt and a central Lewis acidic metal has a high catalytic activity at a high temperature for the copolymerization of an epoxide and carbon dioxide to produce a high molecular weight polycarbonate.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: September 9, 2014
    Assignee: SK Innovation Co., Ltd.
    Inventors: Bun Yeoul Lee, S. Sujith, Eun Kyung Noh, Jae Ki Min
  • Patent number: 8822722
    Abstract: To provide a fluorescent hydrogel having superior detectability of saccharides such as glucose and minimal invasiveness, a method for producing the same, and a sensor for measuring saccharides using the same. A florescent hydrogel having a structure represented by the following chemical formula 1, a method for producing the same, and a sensor for measuring saccharides using the same.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: September 2, 2014
    Assignees: Terumo Kabushiki Kaisha, The University of Tokyo
    Inventors: Yun-Jung Heo, Hideaki Shibata, Tetsuro Kawanishi, Shoji Takeuchi, Yukiko Matsunaga, Teru Okitsu
  • Publication number: 20140221667
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Application
    Filed: April 11, 2014
    Publication date: August 7, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Daniel A. DICKMAN, Dange Vijay KUMAR, Colin O'BRYAN, Roopa RAI, William Dvorak SHRADER
  • Publication number: 20140203251
    Abstract: Provided are a novel compound and an organic electronic device (OED) including the same. The novel compound has better hole injection and hole transport properties than a conventional material, and thus may enhance thermal stability and efficiency when used as a material for a hole injection or hole transport layer of the OED.
    Type: Application
    Filed: May 25, 2012
    Publication date: July 24, 2014
    Applicant: LMS CO., LTD.
    Inventors: Joon Ho Jung, Jeong Og Choi, Oh Kwan Kwon, Ah Reum Hwang
  • Publication number: 20140203382
    Abstract: Boron carbide polymers prepared from orthocarborane icosahedra cross-linked with a moiety A wherein A is selected from the group consisting of benzene, pyridine. 1, 4-diaminobenzene and mixtures thereof give positive magnetoresistance effects of 30%-80% at room temperature. The novel polymers may be doped with transitional metals to improve electronic and spin performance. These polymers may be deposited by any of a variety of techniques, and may be used in a wide variety of devices including magnetic tunnel junctions, spin-memristors and non-local spin valves.
    Type: Application
    Filed: December 6, 2013
    Publication date: July 24, 2014
    Applicant: Quantum Devices, LLC
    Inventors: JEFFRY KELBER, Peter Dowben
  • Publication number: 20140194640
    Abstract: The use of quaternary halogenated ammonium salts for treating leishmaniasis infections and other parasitic diseases is described. Although there have been previous reports in which quaternary ammonium salts are used as antimalarial, antifungal, and antileishmanial compounds, the use of such salts containing a halogenated N-methyl substituent as a therapeutic agent against leishmaniasis had not been reported. The compounds described here, in specific those with a terminal arylalkenyl or diarylalkenyl moiety, are shown to inhibit the growth of Leishmania panamensis parasites, a known causative agent of leishmaniasis disease. In addition, the series of compounds are also extensive against malaria, Chagas disease, toxoplasmosis, and other parasitic diseases.
    Type: Application
    Filed: May 30, 2012
    Publication date: July 10, 2014
    Inventors: Luz Amalia Rios Vasquez, Rogelio Ocampo Cardona, Sandra Milena Duque, Sara Maria Robledo Restrepo, Ivan Dario Velez Bernal, David Leonardo Cedeño Medina, Marjorie Ann Jones
  • Patent number: 8772536
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: July 8, 2014
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Edward J. Olhava, Mihaela Diana Danca
  • Publication number: 20140179631
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: February 25, 2014
    Publication date: June 26, 2014
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Jing Li
  • Publication number: 20140171655
    Abstract: The present invention provides a novel ligand represented by the following formula and a novel transition metal complex having the ligand, which shows superior enantioselectivity and catalytic efficiency, particularly high catalyst activity, in various asymmetric synthesis reactions. A transition metal complex having, as a ligand, a compound represented by the formula wherein R4 is a hydrogen atom or a C1-6 alkyl group optionally having substituent(s), and R5 and R6 are each a C1-6 alkyl group optionally having substituent(s), or the formula is a group represented by the formula wherein ring B is a 3- to 8-membered ring optionally having substituent(s).
    Type: Application
    Filed: February 19, 2014
    Publication date: June 19, 2014
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Mitsuhisa YAMANO, Mitsutaka GOTO, Shinji KAWAGUCHI, Masatoshi YAMADA, Jun-ichi KAWAKAMI
  • Publication number: 20140147934
    Abstract: The present invention provides a glucose sensor having a glucose receptor containing a binding site of formula (I): wherein X, n, m and R1 are defined herein. Also provided is a glucose sensor molecule for use in such a glucose sensor, the glucose sensor molecule containing the binding site of formula (I). The binding site has been found to have particularly good selectivity for glucose.
    Type: Application
    Filed: January 10, 2012
    Publication date: May 29, 2014
    Inventors: Nicholas Paul Barwell, Tony James
  • Publication number: 20140148413
    Abstract: The present embodiments relate to compositions and methods for treating the inflammatory response in a tissue or organ, such as the liver, by contacting the tissue with a tissue-specific gap junction inhibitor; and compositions and methods of reducing the toxicity of an agent by administering a gap junction inhibitor either simultaneously or sequentially with exposure to the agent. For example, inhibition of the liver-specific gap junction connexin 32 by 2 aminoethyoxydiphenyl-borate, effectively treats and/or prevents hepatotoxicity.
    Type: Application
    Filed: June 22, 2011
    Publication date: May 29, 2014
    Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE GENERAL HOSPITAL CORPORATION
    Inventors: Suraj J. Patel, John M. Milwid, Martin L. Yarmush, Kevin R. King
  • Publication number: 20140114074
    Abstract: The invention relates to a process for the preparation of alkali-metal salts with dihydridodicyanoborate anions by reaction of alkali-metal tetrahydridoborates or trihydridocyanoborates with trialkylsilyl cyanide and further reaction thereof in metathesis reactions.
    Type: Application
    Filed: May 23, 2012
    Publication date: April 24, 2014
    Applicant: MERCK PATENT GmbH
    Inventors: Nikolai (Mykola) Ignatyev, Michael Schulte, Eduard Bernhardt, Vera Bernhardt-Pitchougina, Helge Willner
  • Patent number: 8703743
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: April 22, 2014
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Jing Li
  • Patent number: 8680332
    Abstract: The invention relates to disubstituted-aminodifluorosulfinium salts represented by the formula (I). Processes for preparing same and methods of use as deoxofluorinating reagent is also provided.
    Type: Grant
    Filed: June 18, 2010
    Date of Patent: March 25, 2014
    Assignee: Omegachem Inc.
    Inventors: Michel A. Couturier, Alexandre L'Heureux
  • Patent number: 8664439
    Abstract: Graphene, a method of fabricating the same, and a transistor having the graphene are provided, the graphene includes a structure of carbon (C) atoms partially substituted with boron (B) atoms and nitrogen (N) atoms. The graphene has a band gap. The graphene substituted with boron and nitrogen may be used as a channel of a field effect transistor. The graphene may be formed by performing chemical vapor deposition (CVD) method using borazine or ammonia borane as a boron nitride (B—N) precursor.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: March 4, 2014
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Sung-Hoon Lee, Sun-ae Seo, Yun-sung Woo, Hyun-jong Chung, Jin-seong Heo
  • Patent number: 8653258
    Abstract: The present disclosure encompasses compounds and compositions that are useful as specific AI-2 antagonists for the control of bacterial quorum sensing. Although the AI-2 antagonists according to the present disclosure may not have bactericidal effect, their ability to attenuate virulence, drug resistance, and/or biofilm formation have therapeutic benefits. In addition, the AI-2 antagonists of the present disclosure can also be used as tools to probe bacterial AI-2 functions. The present disclosure also encompasses methods for inhibiting or attenuating microbial virulence, biofilm formation, and drug resistance. The methods are suitable for preventing bacteria from accruing and forming extensive biofilms that may be a health or hygiene hazard or a physical issue, such as in the blockage of water or fuel lines.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: February 18, 2014
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Binghe Wang, Nanting Ni, Junfeng Wang, Chung-Dar Lu, Han-Ting Chou, Minyong Li, Shilong Zheng, Yunfeng Cheng, Hanjing Peng
  • Patent number: 8642812
    Abstract: A compound having the formula (I) where each of R1, R2, R3 and R4 is independently C6-C18 aryl-, C5-C8 cycloalkyl-, C6-C18 aryl having at least one C1-C20 alkyl substituent, C5-C8 cycloalkyl having at least one C1-C20 alkyl substituent, C4-C20 branched alkyl-, C16-C20 linear alkyl-, RO—, —NRR?, —PRR?, —SR, fluoro substituted forms thereof, and perfluoro forms thereof: and R5 is C6-C18 aryl-, C3-C8 cycloalkyl-, C6-C18 aryl having at least one C1-C20 alkyl substituent, C5-C8 cycloalkyl having at least one C1-C20 alkyl substituent, C3-C20 branched alkyl-, C2-C30 linear alkyl-, fluoro substituted forms thereof, and perfluoro forms thereof; where R and R? are each independently C6-C18 aryl-, C5-C8 cycloalkyl-, C6-C18 aryl having at least one C1-C20 alkyl substituent, C5-C8 cycloalkyl having at least one C1-C20 alkyl substituent, C4-C20 branched alkyl-, C2-C30 linear alkyl-, fluoro substituted forms thereof, and perfluoro forms thereof; A is N, P, S, or O with the proviso that when A is S, R2 is a nullity; and M is
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: February 4, 2014
    Assignee: Stephan Consulting Corporation
    Inventors: Douglas W. Stephan, Gregory C. Welch, Jenny S. J. McCahill
  • Patent number: 8637703
    Abstract: Methods of synthesizing ammonia borane are provided. The methods comprise reacting at least one amine borane with ammonia such that ammonia borane is produced. Ammonia borane has a chemical formula of NH3.BH3 and provides a good source of storage hydrogen making it useful in a variety of applications including a potential hydrogen source for fuel cells. The methods can further comprise separating the ammonia borane from the other products of the reaction. Exemplary methods can produce ammonia borane having purity greater than about 90 percent. In further examples, the methods can produce ammonia borane having purity greater than about 95 percent or greater than about 99 percent.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: January 28, 2014
    Assignee: The Ohio State University
    Inventors: Sheldon Gerald Shore, Xuenian Chen
  • Patent number: 8637490
    Abstract: Described herein are compounds that may be selectively activated to produce active anti-cancer agents in tumor cells. Also disclosed are pharmaceutical compositions comprising the compounds, and methods of treating cancer using the compounds.
    Type: Grant
    Filed: July 1, 2012
    Date of Patent: January 28, 2014
    Assignee: UWM Research Foundation, Inc.
    Inventors: Xiaohua Peng, Yunyan Kuang, Sheng Cao, Wenbing Chen, Yibin Wang
  • Publication number: 20140011998
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: July 3, 2013
    Publication date: January 9, 2014
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Jing Li
  • Publication number: 20130331608
    Abstract: Disclosed are a novel diimmonium-based compound that has low light absorption in visible light region and has superior light absorption efficiency in near infrared region, and has superior durability and weatherability, and a near infrared absorption filter using the same. The diimmonium-based compound is represented by the formula 1 of claim 1.
    Type: Application
    Filed: December 26, 2011
    Publication date: December 12, 2013
    Applicant: SK CHEMICALS CO., LTD.
    Inventors: Ju-Sik Kang, Jeong-Ho Park, Yu-Mi Chang
  • Patent number: 8603328
    Abstract: Supercritical carbon dioxide extraction of corn germ oil from corn germ utilizing extraction conditions adapted to a dry corn fractionation ethanol production process.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: December 10, 2013
    Assignee: MOR Supercritical, LLC
    Inventors: Kenneth E. DeLine, Daniel L. Claycamp, Daniel Fetherston, Rodger T. Marentis
  • Publication number: 20130281728
    Abstract: A compound having a structure of: wherein each of R1-R6 is individually H, halogen, hydroxyl, amino, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted acyl, optionally substituted acyloxy, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted heterocycloxy, halogenated alkyl, thioether, optionally substituted thiol, ester, aminocarbonyl, amido, nitro, silyl, sulfinyl, sulfonyl, or phosphino.
    Type: Application
    Filed: April 18, 2013
    Publication date: October 24, 2013
    Inventors: Shih-Yuan Liu, Senmiao Xu
  • Patent number: 8563533
    Abstract: The invention provides compounds and methods for inhibiting proteases. One aspect of the invention features pro-soft inhibitors which react with an activating protease to release an active inhibitor moiety in proximity to a target protease. In certain instances, compounds inhibit proteasomes and/or post-proline cleaving enzymes (PPCE), such as dipeptidyl peptidase IV. The compounds of the invention provide a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: October 22, 2013
    Assignee: Trustees of Tufts College
    Inventors: William W. Bachovchin, Hung-sen Lai, Wengen Wu
  • Publication number: 20130260471
    Abstract: The invention concerns the use of cyclic azaboronates as sensitive materials in sensors for the detection of the presence of peroxides, in particular hydrogen peroxide, in a gaseous environment. It further concerns new cyclic azaboronates, as well as sensors comprising these azaboronates as sensitive materials. Applications: Fight against terrorism, monitoring for security purposes of sites in which peroxides or peroxidable compounds are manufactured, stored, and/or used, monitoring of atmospheric pollution, etc.
    Type: Application
    Filed: October 17, 2011
    Publication date: October 3, 2013
    Inventors: Thomas Caron, Myriam Bouhadid, Eric Pasquinet, Pierre Montmeat, Francoise Serein-Spirau
  • Patent number: 8530694
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: September 10, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Edward J. Olhava, Mihaela Diana Danca
  • Patent number: 8524946
    Abstract: A production method of a compound containing a primary, secondary, or tertiary aminomethyl aromatic ring of the present invention includes: using a fluoroboron compound or a dimer thereof, or solvates thereof, which are represented by a formula (I): Ra(Rb)N—CH2—BF3M??(I) as an aminomethylating agent for an aromatic ring; and reacting the aminomethylating agent with an aromatic ring-containing compound, which can react with the aminomethylating agent, under the presence of a metal catalyst such as a palladium compound so as to perform the direct aminomethylation of the aromatic ring.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: September 3, 2013
    Assignee: Eisai R&D Management Co., Ltd.
    Inventor: Keigo Tanaka
  • Patent number: 8513218
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: August 20, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul E. Fleming, Jing Li
  • Publication number: 20130196433
    Abstract: Methods for enhancing cellular uptake of cargo molecules by boronating the cargo molecule, particularly with one or more phenylboronic acid groups. Cellular uptake includes at least partial uptake into the cytosol. Boronation includes ligating, crosslinking or otherwise bonding one or more phenylboronic acids substituted to contain a reactive group to a cargo molecule. Boronation also includes ligating, crosslinking or otherwise bonding a phenylboronated oligopeptide to a cargo molecule. The phenylboronate groups are optionally conjugated to the cargo molecule via linking moieties that can be selectively cleaved, such cleavable linkers can allow the phenylboronate groups to be removed from the cargo molecule after the boronated cargo molecule is introduced into the cell. The invention includes certain phenylboronates which are boronation reagents, certain boronated oligopeptides and certain boronated peptides and proteins.
    Type: Application
    Filed: January 18, 2013
    Publication date: August 1, 2013
    Inventors: Ronald T. Raines, Gregory Ellis, Michael Palte
  • Publication number: 20130178405
    Abstract: Tetrafluoroboric acid and an organic nitrogenous base, related compounds and compositions, as can be used in conjunction with various methods of cleaning and/or the treatment of substrate surfaces.
    Type: Application
    Filed: March 4, 2013
    Publication date: July 11, 2013
    Applicant: Vitech International, Inc.
    Inventor: Vitech International, Inc.
  • Patent number: 8481785
    Abstract: The invention pertains to new materials based on sterically inhibited donor arylboranes for the improvement of electron injection and electron transport in organic electronic components like organic light-emitting diodes (OLED's), organic field effect transistors (OFET's), and on organic photovoltaics based components, in particular, organic solar cells.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: July 9, 2013
    Assignee: Osram Opto Semiconductors GmbH
    Inventor: Andreas Kanitz
  • Publication number: 20130161564
    Abstract: The invention discloses the incorporation of nanostructured additives into high-performance, hydrogen-rich polymeric materials to provide radiation shields for use against Galactic Cosmic Radiation and Solar Energetic Particles as well as secondary particulate and electromagnetic radiation resulting from nuclear reactions within the shield. Nanostructured materials are defined as having at least one dimension in the nanometer range, and may include metallic and metal-oxide nanoparticles, nanotubes, nanoclays, coated polymeric nanoparticles and pairs of materials forming a nanostructured interface. Functionalization of additives is performed to increase their compatability with polymeric materials. Hydrogen-rich polymers refer to those having interstitial hydrogen or hydrogen-containing materials pendant to the polymer backbone.
    Type: Application
    Filed: December 22, 2011
    Publication date: June 27, 2013
    Applicant: International Scientific Technologies, Inc.
    Inventors: Russell Joseph Churhill, Eugene Canlas Aquino, Robert Orwoll, Richard Kiefer, Howard Paul Groger
  • Patent number: 8461134
    Abstract: This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: June 11, 2013
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Vincent S. Hernandez, Xianfeng Li, Suoming Zhang, Tsutomu Akama, Yanchen Zhang, Yang Liu, Jacob J. Plattner, Michael Richard Kevin Alley, Yasheen Zhou, James A. Nieman
  • Patent number: 8415327
    Abstract: Methods and compositions involving a class of boron-protected phenylphosphine agents having increased cell permeability and having improved chemical stability for treating or for preventing cell death-related diseases or conditions in a human or a non-human animal.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: April 9, 2013
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Leonard A. Levin, Yun Luo
  • Patent number: 8415328
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: April 9, 2013
    Assignee: Pharmacyclics, Inc
    Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader, Kieron Wesson
  • Publication number: 20130066264
    Abstract: Disclosed are a sugar-responsive gel and a medicine administering device having a pKa more suitable for use in a body environment and capable of administering medicine more autonomously than before. A sugar-responsive gel and an insulin administering device having a pKa more suitable for use in a body environment and capable of administering insulin more autonomously than before, wherein under a body condition of pKa of 7.4 or less and temperature of 35° C.-40° C., when the glucose concentration increases, insulin can be released from a gel body in response thereto, and when the glucose concentration decreases, insulin release from the gel body can be suppressed.
    Type: Application
    Filed: May 24, 2011
    Publication date: March 14, 2013
    Applicant: NATIONAL INSTITUTE FOR MATERIALS SCIENCE
    Inventors: Akira Matsumoto, Takehiko Ishii, Kazunori Kataoka, Yuji Miyahara